

Official Letter

Boditech Med Inc.
43, Geodudanji 1-gil, Dongnae-myeon,
Chuncheon-si, Gangwon-do, 24398
Republic of Korea
Date: March 26, 2025

To Whom It May Concern,

We, Boditech Med Inc., a corporation duly incorporated and existing under the laws of the Republic of Korea, with our principal place of business at the address stated above, hereby certify the following:

The product **AFIAS MxA/CRP**, manufactured by Boditech Med Inc., can be used reliably with both venous blood and capillary blood samples.

This declaration is based on clinical data from the following studies:

- A prospective clinical study for MxA, conducted at Gyeongsang National University Changwon Hospital in Korea with 117 subjects, showed no significant difference between venous and capillary blood samples.
- A clinical performance evaluation for CRP, conducted at Hillerød Hospital in Denmark with 114 subjects, also demonstrated equivalence between venous and capillary blood results.

As AFIAS MxA/CRP measures both biomarkers simultaneously using the same fluorescence-based immunoassay principle, and since each biomarker has independently shown equivalent performance across blood sample types, it is scientifically valid to conclude that AFIAS MxA/CRP is suitable for use with both venous and capillary whole blood samples.

Yours faithfully,

